Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
69,251.91 +3,110.88 (+4.70%) CMC Crypto 200
1,467.01 +112.60 (+8.31%)
GSK Nov 2024 41.000 call
| Previous close | 5.90 |
| Open | 5.50 |
| Bid | 3.70 |
| Ask | 6.30 |
| Strike | 41.00 |
| Expiry date | 2024-11-15 |
| Day's range | 5.50 - 5.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 230 |
ReutersGSK whistleblower claims drugmaker cheated US government over Zantac cancer risk
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
- Reuters
GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales
Drugmaker GlaxoSmithKline Pharma India reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol. Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.
Evening StandardFTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
